Myeloma

Watch Dr. Saad Z. Usmani, Dr. Ben Marcus and Stan Wagner discuss their participation in the Moving Mountains for Multiple Myeloma program, during the CURE Educated Patient Multiple Myeloma Summit.

Watch Kristie L. Kahl, Donna and Jack McNutt, Dr. Noopur Raje, and Grace Allison, discuss treating myeloma long term, during the CURE Educated Patient Multiple Myeloma Summit.

Watch Dr. Saad Z. Usmani, Dr. Krina K. Patel, Dr. Noa Biran, and Jenny Ahlstrom, answer audience Q&A during the CURE Educated Patient Multiple Myeloma Summit.

Watch Dr. Noa Biran, an associate professor of medicine in the division of multiple myeloma at The John Theurer Cancer Center at Hackensack University Medical Center, discuss treatment for relapsed/refractory myeloma.

Watch Dr. Krina K. Patel, an associate professor and center medical director for the Department of Lymphoma-Myeloma at The University of Texas MD Anderson Cancer Center discuss treatment for newly diagnosed myeloma.

Watch Saad Z. Usmani, MD, MBA, with Carlyn Rose Tan, MD; Neha S. Korde, MD; and Kenny Capps answer audience Q&A during the CURE Educated Patient Multiple Myeloma Summit.

Watch Dr. Carlyn Rose Tan, an assistant attending in myeloma service at Memorial Sloan Kettering Cancer Center, present on risk stratification for newly diagnosed patients.

Watch Dr. Neha S. Korde, an assistant professor in multiple myeloma service in the Division of Hematology at Memorial Sloan Kettering Cancer Center, present on MGUS/smoldering myeloma.

To address symptoms from myeloma that is resistant to treatment, education and communication with care teams are key.

Bone pain is a common symptom that patients with multiple myeloma face, but some may find relief with treatments and exercise.

One of the hurdles, according to the study’s lead author, is that many patients with cancer are worried about receiving a placebo in a clinical trial.

In honor of CURE®’s 20th anniversary, we spoke with experts on how the past 20 years have revolutionized multiple myeloma treatment.

Many things can influence a patient’s response to the COVID-19 vaccine, such as their treatments or whether they have a higher tumor burden.

It can be difficult for patients to go about their daily life with this bone pain, so what can help?

As part of its “Speaking Out” video series, CURE® spoke with Throwing Bones founder Kenny Capps about the importance of patient-physician communication during a myeloma journey.

Donna McNutt uses her love of fashion to find confidence and motivation — and shares it with others — after a myeloma diagnosis.

When cancer harms the body’s ability to make antibodies, what does that mean for the efficacy of vaccines?

Durable and deep responses occurred in patients with multiple myeloma after use of a particular CAR-T cell therapy

As more and more people in their 20s and 30s begin to receive diagnoses of multiple myeloma, a type of blood cancer, one expert stresses that continued research to improve survival in this patient population is critical.

The FDA plans to speed up its review of HPN217 for the treatment of patients with relapsed, refractory multiple myeloma who have received at least four prior lines of therapy.

From Emilio Delgado, the actor who portrayed Luis on “Sesame Street”, dying from multiple myeloma to actor Benjamin Bratt discussing his wife’s breast cancer journey, here’s what’s happening in the cancer space this week.

The recent FDA approval of the CAR-T cell therapy Carvykti represents a life-changing advancement for patients with multiple myeloma whose disease progressed after countless other treatments, according to an expert.

Maintenance therapy with Ninlaro and Revlimid in patients with recently diagnosed multiple myeloma who underwent a stem cell transplant may safely improve survival, although more research is needed especially in high-risk patients.

Maintaining a healthy diet during treatment may help combat side effects.

Although multiple myeloma survival rates have improved over the past 20 years, the survival gap among socioeconomic groups has widened.

As part of its Speaking Out video series, CURE spoke with Throwing Bones founder, Kenny Caps, about treating myeloma as a chronic disease and how the multidisciplinary approach to care can assist in challenges, like financial toxicity.

As part of its Speaking Out video series, CURE spoke with Throwing Bones founder, Kenny Caps, about raising awareness for multiple myeloma, and why sharing one’s story is helpful for others.

Ninety-eight percent of patients with pretreated relapsed/refractory myeloma responded to treatment with Carvykti, a newly approved CAR-T cell therapy for this patient population.

A clinical trial to evaluate Descartes-25, a novel allogeneic RNA cell therapy, for multiple myeloma has officially treated its first patient and is now recruiting in certain locations.

Although patients with multiple myeloma may be concerned that a reduction in treatment dose may be less effective, an expert from The Tisch Cancer Institute stresses that it may be more beneficial.